<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144518</url>
  </required_header>
  <id_info>
    <org_study_id>17039</org_study_id>
    <nct_id>NCT03144518</nct_id>
  </id_info>
  <brief_title>Mood and Influenza Vaccine Response: A Feasibility Trial</brief_title>
  <official_title>A Feasibility Trial of a Brief Positive Affect Intervention to Improve the Effectiveness of Influenza Vaccine Response in Older Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 2-arm, parallel, randomised controlled feasibility trial of a brief video
      intervention designed to induce positive affect (mood) in older adults in primary care
      settings prior to the receipt of influenza vaccination. Participants will be randomised into
      two conditions: experimental and active control. In the experimental condition, participants
      will view the approximately 15 minute long intervention video immediately prior to
      vaccination. In the active control condition, participants will view a matched video that is
      designed to be mood neutral. Pre-and-post positive affect levels will be assessed by
      self-report questionnaires. Immune response to the intervention and vaccination responses
      will be assessed in saliva and serum samples respectively.

      The objectives of the study are to assess the impact of the intervention on mood, immune
      function, and antibody response to influenza vaccination in older adults. This feasibility
      trial will also allow data collection on exploring recruitment, attrition, intervention
      engagement, and practicality of collecting clinical data available through electronic records
      to inform the design of a future definitive trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Centers for Disease Control (CDC) describe vaccinations as among the 10 most significant
      health achievements ever documented; and for many conditions they have been an unmitigated
      success (e.g., smallpox). There are, however, several populations in whom vaccine
      effectiveness is far from optimal. These populations are typically contending with underlying
      immune impairment by virtue of their advancing age and/or the presence of co-existing
      diseases (e.g., cancer). As a consequence, vaccines are most likely to fail those whom they
      most seek to benefit: individuals at the greatest risk of ill health.

      This has prompted research into treatments that enhance immune function prior to vaccination,
      so called vaccine adjuvants. The aim of such treatments is to optimise the response the
      immune system makes to the vaccine antigens and, in so doing, increase the likelihood that
      the vaccine confers protection.

      One area in which there has been interest is in the potential for developing
      psycho-behavioural vaccine adjuvants. There is considerable evidence that psychological and
      behavioural factors can modulate immunity; with diet, physical activity, stress, affect,
      sleep and social support all associated with immune response.

      The investigators recently conducted a longitudinal observational cohort study of multiple
      psychological (positive affect, negative affect, stress) and behavioural (physical activity,
      sleep, diet) influences on short and long-term antibody responses to influenza vaccination in
      older adults. This identified positive affect as the most influential psycho-behavioural
      factor on influenza-specific antibody responses, independently predicting both short and
      long-term antibody responses in the weakest immunogenic strain above and beyond known
      demographic and clinical determinants. Intriguingly, the investigators also observed
      preliminary evidence that positive affect on the day of vaccination was more predictive of
      antibody responses following vaccination than mood measured over the longer period
      surrounding vaccination. As influenza-specific antibodies are a well-established correlate of
      protection from serologically and clinically diagnosed influenza incidence, these data
      suggest that increasing positive affect immediately prior to vaccination could be used as a
      non-pharmacological vaccine adjuvant.

      Through a series of systematic steps, including focus groups and interviews with older adults
      and health care professionals, the investigators have recently developed a brief, positive
      affect intervention - designed to improve short-term mood in older adults and be deliverable
      within primary care. It is hoped this could act as a psycho-behavioural adjuvant to enhance
      poor responses to influenza vaccination in older adults. Before performing a definitive trial
      of the intervention's effectiveness, a feasibility trial is needed for number of reasons:

        1. To assess whether our intervention can enhance positive affect (mood)

        2. To collect information regarding likely recruitment, effect sizes, and attrition rates
           for informing the necessary size of a larger definitive trial

        3. To examine the practicality and acceptability of delivering the intervention in routine
           primary care settings

        4. To explore the feasibility of obtaining outcome data on healthcare usage for a large
           scale trial (hospitalisation, GP visits for flu-like symptoms from medical records)

      In line with the above, the investigators will be conducting a 2-arm, parallel, randomised
      controlled feasibility trial of a brief video intervention designed to induce positive affect
      (mood) in older adults in primary care settings prior to the receipt of influenza
      vaccination. Participants will be randomised into two conditions: experimental and active
      control. In the experimental condition, participants will view the approximately 15 minute
      long intervention video immediately prior to vaccination. In the active control condition,
      participants will view a matched video that is designed to be mood neutral. Pre-and-post
      positive affect levels will be assessed by self-report questionnaires. Immune response to the
      intervention and vaccination responses will be assessed in saliva (pre/post intervention) and
      serum samples (pre/4 weeks post-vaccination/16weeks post-vaccination) respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood Outcome Scores [Multiple]</measure>
    <time_frame>Baseline, Immediately Post Intervention (i.e, 15 minutes post-baseline).</time_frame>
    <description>Affective Slider (Betella &amp; Verschure, 2016), consists of two single item visual analogue scales. Scores for each are presented as a value from 0 to 100 with higher scores indicating greater pleasure (VAS-Valence) and arousal (VAS-Arousal).
Positive and Negative Affect Schedule (Watson et al., 1988). Positive and negative affect subscales were created by summing the scores of positive and negative adjectives respectively. For each sub scale, minimum score = 10, maximum score = 50 with higher scores indicating greater positive and negative affect respectively.
Pictorial scale of positive affect (unvalidated, internally developed). Participants completed a single-item photo-based measure of positive affect tailored for older adults. Participants were presented with six groups of images depicting varying degrees of positive affect, and indicate which best reflected how they felt at that moment. Minumum score 1, maximum score 6, higher scores indicate greater positive affect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recruitment</measure>
    <time_frame>Baseline</time_frame>
    <description>Recruitment rates to inform a future definitive trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attrition</measure>
    <time_frame>4 weeks (post-vaccination), 16 Weeks (post-vaccination)</time_frame>
    <description>Attrition - to inform a future definitive trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretory IgA Response</measure>
    <time_frame>Baseline, Immediately Post Intervention (i.e, 15 minutes post-baseline).</time_frame>
    <description>Secretory IgA levels measured in saliva samples via ELISA. This is a non-specific measure of immunological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Specific IgG Response</measure>
    <time_frame>4 weeks (post-vaccination), 16 Weeks (post-vaccination)</time_frame>
    <description>IgG levels against the 4 vaccine strains measured via ELISA.
Values represent equivalent ug/ml based on diluted sample absorbance value interpolation against a standard IgG curve, multiplied by the serum dilution score (i.e., 4000).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization</measure>
    <time_frame>Baseline to 6 months post-vaccination</time_frame>
    <description>Via medical records, we assessed health care usage potentially attributable to flu-like symptoms (e.g., GP visits, hospitalisation, antibiotic prescription) during the 6 months post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Vaccination; Infection</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive Affect Intervention</intervention_name>
    <description>See Previous Description</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neutral Control Intervention</intervention_name>
    <description>See Previous Description</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</intervention_name>
    <description>Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females aged 65-85 years (inclusive)

          -  Received influenza vaccination for the 2016/17 season

          -  Eligible to receive 2017/18 influenza vaccination as part of usual care

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Males and Females aged less than 65 or over 85 years (exclusive)

          -  Did not receive influenza vaccination for the 2016/17 season

          -  Ineligible to receive 2017/18 influenza vaccination as part of usual care

          -  Unable to provide informed consent

        Deemed by health care provider to be:

          -  Too physically frail to participate

          -  Diagnosed with dementia or other cognitive condition which would make participation
             difficult

          -  Insufficient command of English language

          -  Influenza vaccination contraindicated

          -  Sufficiently impaired of hearing or vision that exposure to the intervention or
             control video content as intended would be compromised

          -  Those for whom the collection of blood samples is contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, Santosham M, Schmitt HJ. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008 Feb;86(2):140-6. Review.</citation>
    <PMID>18297169</PMID>
  </reference>
  <reference>
    <citation>Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet. 2005 Feb 26-Mar 4;365(9461):773-80. Review.</citation>
    <PMID>15733718</PMID>
  </reference>
  <reference>
    <citation>Calder PC, Jackson AA. Undernutrition, infection and immune function. Nutr Res Rev. 2000 Jun;13(1):3-29. doi: 10.1079/095442200108728981.</citation>
    <PMID>19087431</PMID>
  </reference>
  <reference>
    <citation>Simpson R, Spielmann G. Exercise and Immunosenescence. In: Bosch J, Phillips A, Lord J, eds. Immunosenescence. New York: : Springer Science 2013. 159-78.</citation>
  </reference>
  <reference>
    <citation>Global Public Health Achievements Team CDC. Ten Great Public Health Achievements-Worldwide, 2001-2010 (Reprinted from MMWR vol 60, pg 814-818, 2011). JAMA 2011;306:484-7.</citation>
  </reference>
  <reference>
    <citation>Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004 Jul;130(4):601-30.</citation>
    <PMID>15250815</PMID>
  </reference>
  <reference>
    <citation>Pressman SD, Cohen S. Does positive affect influence health? Psychol Bull. 2005 Nov;131(6):925-971. doi: 10.1037/0033-2909.131.6.925. Review.</citation>
    <PMID>16351329</PMID>
  </reference>
  <reference>
    <citation>Bryant PA, Trinder J, Curtis N. Sick and tired: Does sleep have a vital role in the immune system? Nat Rev Immunol. 2004 Jun;4(6):457-67. Review.</citation>
    <PMID>15173834</PMID>
  </reference>
  <reference>
    <citation>Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006 Aug;29(4):377-87. Epub 2006 Jun 7. Review.</citation>
    <PMID>16758315</PMID>
  </reference>
  <reference>
    <citation>Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010 Mar 8;10:18. doi: 10.1186/1471-2288-10-18.</citation>
    <PMID>20210985</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>April 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2019</results_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positive Affect</keyword>
  <keyword>Positive Mood</keyword>
  <keyword>Influenza Vaccination</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Randomised Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03144518/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Note: 3 Participants were not randomised to condition, as they did not attend primary session.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
        <group group_id="P2">
          <title>Active Control</title>
          <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Outcome (Mood)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>4 Weeks Post-Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>16 Week Post-Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
        <group group_id="B2">
          <title>Active Control</title>
          <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Missing Data count n=1</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.6" spread="4.6"/>
                    <measurement group_id="B2" value="73.3" spread="5.1"/>
                    <measurement group_id="B3" value="72.95" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Respond</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Single, never married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Separated/divorced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Widowed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cohabiting</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not Respond</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest Level of Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>School</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Undergraduate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postgraduate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not respond</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Independent Living</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest Ever Total Household Income</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ £14,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>£15,000–£24,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>£25,000–£34,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>£35,000–£49,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>£50,000–£74,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>£75,000–£99,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ £100,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did Not Respond</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Health Status</title>
          <description>Health Status Questionnaire 2.0 (Barry, Kaiser, &amp; Atwood, 2007). Responses are weighted and summed as per published guidelines in above reference to calculate a total perceived health status score ranging from a minimum of 0 to a maximum of 800, with higher scores indicating greater perceived health.</description>
          <population>Missing Data Count: n=6</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="555.7" spread="175.1"/>
                    <measurement group_id="B2" value="555.1" spread="169.9"/>
                    <measurement group_id="B3" value="555.41" spread="171.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trait Positive Affect</title>
          <description>Trait positive affect was measured using positive affect sub scale from the Positive and Negative Affect Schedule (Watson et al., 1988). Positive subscale (α = .92) was created by summing the scores of positive adjectives. Minimum score 10, Maximum Score 50, with higher scores indicating greater trait positive affect.</description>
          <population>Missing Data Count: n=8</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="8.6"/>
                    <measurement group_id="B2" value="33.8" spread="8.1"/>
                    <measurement group_id="B3" value="33.65" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trait Optimism</title>
          <description>Trait optimism was measured using the Revised Life Orientation Test (Scheier, Carver, &amp; Bridges, 1994). Six items are used to compute a trait optimism score (α = .73) in line with published guidelines. Minimum Score 0, Maximum Score 24 with higher scores indicating with greater optimism.</description>
          <population>Missing Data Count: n=7</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="4.8"/>
                    <measurement group_id="B2" value="15.3" spread="4.5"/>
                    <measurement group_id="B3" value="15.68" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trait Emotional Reactivity</title>
          <description>Trait emotional reactivity was measured using the 21-item Emotional Reactivity Scale (Nock, Wedig, Holmberg, &amp; Hooley, 2008). Items scores are summed (α = .96). Minimum score 21, maximum score 105, with greater scores indicating greater trait emotional reactivity.</description>
          <population>Missing Data Count: n=8</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="17.2"/>
                    <measurement group_id="B2" value="41.3" spread="16.0"/>
                    <measurement group_id="B3" value="40.59" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Vaccination IgG</title>
          <description>Values represent equivalent ug/ml based on diluted sample absorbance value interpolation against a standard IgG curve, multiplied by the serum dilution score (i.e., 4000).</description>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>A/Michigan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187.2" spread="112.4"/>
                    <measurement group_id="B2" value="156.6" spread="103.1"/>
                    <measurement group_id="B3" value="172.05" spread="108.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Hong-Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238.0" spread="119.9"/>
                    <measurement group_id="B2" value="241.0" spread="158.1"/>
                    <measurement group_id="B3" value="239.50" spread="139.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107.0" spread="54.1"/>
                    <measurement group_id="B2" value="118.9" spread="78.7"/>
                    <measurement group_id="B3" value="112.90" spread="67.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144.4" spread="85.1"/>
                    <measurement group_id="B2" value="183.2" spread="146.2"/>
                    <measurement group_id="B3" value="163.61" spread="117.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trait Negative Affect</title>
          <description>Trait negative affect was measured using the negative affect sub scale of Positive and Negative Affect Schedule (Watson et al., 1988). Negative affect subscales (α = .92) was created by summing the scores of negative adjectives. Minimum score 10, maximum score 50 with higher scores indicating greater trait negative affect.</description>
          <population>Missing Data Count n=11</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="6.7"/>
                    <measurement group_id="B2" value="15.5" spread="6.4"/>
                    <measurement group_id="B3" value="15.35" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mood Outcome Scores [Multiple]</title>
        <description>Affective Slider (Betella &amp; Verschure, 2016), consists of two single item visual analogue scales. Scores for each are presented as a value from 0 to 100 with higher scores indicating greater pleasure (VAS-Valence) and arousal (VAS-Arousal).
Positive and Negative Affect Schedule (Watson et al., 1988). Positive and negative affect subscales were created by summing the scores of positive and negative adjectives respectively. For each sub scale, minimum score = 10, maximum score = 50 with higher scores indicating greater positive and negative affect respectively.
Pictorial scale of positive affect (unvalidated, internally developed). Participants completed a single-item photo-based measure of positive affect tailored for older adults. Participants were presented with six groups of images depicting varying degrees of positive affect, and indicate which best reflected how they felt at that moment. Minumum score 1, maximum score 6, higher scores indicate greater positive affect.</description>
        <time_frame>Baseline, Immediately Post Intervention (i.e, 15 minutes post-baseline).</time_frame>
        <population>Missing Data for some outcome measures - i.e., incomplete scale</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
        </group_list>
        <measure>
          <title>Mood Outcome Scores [Multiple]</title>
          <description>Affective Slider (Betella &amp; Verschure, 2016), consists of two single item visual analogue scales. Scores for each are presented as a value from 0 to 100 with higher scores indicating greater pleasure (VAS-Valence) and arousal (VAS-Arousal).
Positive and Negative Affect Schedule (Watson et al., 1988). Positive and negative affect subscales were created by summing the scores of positive and negative adjectives respectively. For each sub scale, minimum score = 10, maximum score = 50 with higher scores indicating greater positive and negative affect respectively.
Pictorial scale of positive affect (unvalidated, internally developed). Participants completed a single-item photo-based measure of positive affect tailored for older adults. Participants were presented with six groups of images depicting varying degrees of positive affect, and indicate which best reflected how they felt at that moment. Minumum score 1, maximum score 6, higher scores indicate greater positive affect.</description>
          <population>Missing Data for some outcome measures - i.e., incomplete scale</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Intervention VAS-Valence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" spread="15.7"/>
                    <measurement group_id="O2" value="79.8" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention VAS-Arousal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" spread="16.8"/>
                    <measurement group_id="O2" value="79.8" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Pictorial Scale</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.1"/>
                    <measurement group_id="O2" value="4.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention PANAS Positive Affect</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="8.4"/>
                    <measurement group_id="O2" value="35.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention PANAS Negative Affect</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="3.0"/>
                    <measurement group_id="O2" value="11.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention VAS-Valence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="19.2"/>
                    <measurement group_id="O2" value="80.5" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention VAS-Arousal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="19.0"/>
                    <measurement group_id="O2" value="80.9" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention Pictorial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.5"/>
                    <measurement group_id="O2" value="4.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention PANAS Postive Affect</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="7.2"/>
                    <measurement group_id="O2" value="34.6" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention PANAS Negative Affect</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="4.0"/>
                    <measurement group_id="O2" value="12.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAS-Valence Scores</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.005</p_value>
            <p_value_desc>ANCOVA, controlling for pre-intervention levels</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA, controlling for pre-intervention levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.079</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.014</ci_lower_limit>
            <ci_upper_limit>.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAS-Arousal Scores</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.047</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-intervention scores</method_desc>
            <param_type>Partial Eta-Squared</param_type>
            <param_value>.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pictorial Scale</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-intervention levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.096</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.022</ci_lower_limit>
            <ci_upper_limit>.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PANAS Positive Affect Scores</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.697</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for baseline levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.002</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.036</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PANAS Negative Affect Scores</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.462</p_value>
            <method>ANCOVA</method>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.005</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recruitment</title>
        <description>Recruitment rates to inform a future definitive trial</description>
        <time_frame>Baseline</time_frame>
        <population>Total Population that received study Invitation</population>
        <group_list>
          <group group_id="O1">
            <title>Whole Trial</title>
            <description>Recruitment Details are presented for trial as a whole</description>
          </group>
        </group_list>
        <measure>
          <title>Recruitment</title>
          <description>Recruitment rates to inform a future definitive trial</description>
          <population>Total Population that received study Invitation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Expressed Interest, but not consented</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Consented, but not randomised</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Randomised</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did Not Express Interest</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attrition</title>
        <description>Attrition - to inform a future definitive trial</description>
        <time_frame>4 weeks (post-vaccination), 16 Weeks (post-vaccination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
        </group_list>
        <measure>
          <title>Attrition</title>
          <description>Attrition - to inform a future definitive trial</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Attendance at 4 Week Follow-up</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attendance at 16 Week Follow up</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secretory IgA Response</title>
        <description>Secretory IgA levels measured in saliva samples via ELISA. This is a non-specific measure of immunological response</description>
        <time_frame>Baseline, Immediately Post Intervention (i.e, 15 minutes post-baseline).</time_frame>
        <population>Missing Data Count n=15</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
        </group_list>
        <measure>
          <title>Secretory IgA Response</title>
          <description>Secretory IgA levels measured in saliva samples via ELISA. This is a non-specific measure of immunological response</description>
          <population>Missing Data Count n=15</population>
          <units>Flow Rate (ug/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention Flow Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" spread="76.4"/>
                    <measurement group_id="O2" value="94.1" spread="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Flow Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.7" spread="107.5"/>
                    <measurement group_id="O2" value="144.7" spread="142.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.806</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-intervention levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.001</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.031</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Specific IgG Response</title>
        <description>IgG levels against the 4 vaccine strains measured via ELISA.
Values represent equivalent ug/ml based on diluted sample absorbance value interpolation against a standard IgG curve, multiplied by the serum dilution score (i.e., 4000).</description>
        <time_frame>4 weeks (post-vaccination), 16 Weeks (post-vaccination)</time_frame>
        <population>Missing Data Count: n=1 for 4 weeks post-vaccination, n=5 for 16 weeks post-vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Specific IgG Response</title>
          <description>IgG levels against the 4 vaccine strains measured via ELISA.
Values represent equivalent ug/ml based on diluted sample absorbance value interpolation against a standard IgG curve, multiplied by the serum dilution score (i.e., 4000).</description>
          <population>Missing Data Count: n=1 for 4 weeks post-vaccination, n=5 for 16 weeks post-vaccination</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks Post-Vaccination A/Michigan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.28" spread="134.52"/>
                    <measurement group_id="O2" value="208.81" spread="122.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Post-Vaccination A/Hong-Kind</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.68" spread="138.88"/>
                    <measurement group_id="O2" value="284.96" spread="138.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Post-Vaccination B/Brisbane</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.30" spread="56.36"/>
                    <measurement group_id="O2" value="127.25" spread="63.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Post-Vaccination B/Phuket</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.30" spread="123.96"/>
                    <measurement group_id="O2" value="229.57" spread="135.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks Post-Vaccination A/Michigan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.69" spread="131.90"/>
                    <measurement group_id="O2" value="203.03" spread="119.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks Post-Vaccination A/Hong-Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.67" spread="126.72"/>
                    <measurement group_id="O2" value="288.75" spread="180.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks Post-Vaccination B/Brisbane</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.49" spread="56.40"/>
                    <measurement group_id="O2" value="144.47" spread="76.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks Post-Vaccination B/Phuket</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.10" spread="124.90"/>
                    <measurement group_id="O2" value="271.70" spread="176.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>4 Weeks A/Hong-Kong</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.438</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for Pre-Vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.006</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/Hong-Kong 16 Weeks Post-Vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.516</p_value>
            <method>ANCOVA</method>
            <method_desc>controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.004</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/Michigan 4 weeks post-vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.671</p_value>
            <method>ANCOVA</method>
            <method_desc>controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.002</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/Michigan 16 weeks post-vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.980</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane 4 weeks post-vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.409</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.007</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane 16 weeks post-vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.377</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.008</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.062</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Phuket 4 weeks post-vaccination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.892</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.008</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Note: The study was not powered a priori to detect significant differences in these outcomes.</non_inferiority_desc>
            <p_value>.426</p_value>
            <method>ANCOVA</method>
            <method_desc>Controlling for pre-vaccination levels</method_desc>
            <param_type>Partial Eta Squared</param_type>
            <param_value>.007</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.000</ci_lower_limit>
            <ci_upper_limit>.058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Utilization</title>
        <description>Via medical records, we assessed health care usage potentially attributable to flu-like symptoms (e.g., GP visits, hospitalisation, antibiotic prescription) during the 6 months post-vaccination</description>
        <time_frame>Baseline to 6 months post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
          <group group_id="O2">
            <title>Active Control</title>
            <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Utilization</title>
          <description>Via medical records, we assessed health care usage potentially attributable to flu-like symptoms (e.g., GP visits, hospitalisation, antibiotic prescription) during the 6 months post-vaccination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GP Consultations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nurse Consultations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Out of Hours/Telephone Conversations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency Department Consultations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibiotic Prescriptions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Investigations (e.g., Xray)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During Primary Study Period - Baseline to 16 weeks post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie’s; A room with a view – faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together – The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
Positive Affect Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
        <group group_id="E2">
          <title>Active Control</title>
          <description>Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
Neutral Control Intervention: See Previous Description
Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care): Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study did not include a usual care comparator. Blinding potentially compromised by common reactions of participants to the positive mood intervention (e.g., laughter). Demand characteristics. Lack of ethnic diversity within sample</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Kieran Ayling</name_or_title>
      <organization>University of Nottingham</organization>
      <phone>+44 1158466908</phone>
      <email>kieran.ayling@nottingham.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

